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Low-Dose Aspirin Acetylates Cyclooxygenase-1
in Human Colorectal Mucosa: Implications for
the Chemoprevention of Colorectal Cancer
P Patrignani1,2, A Sacco1,2, C Sostres3, A Bruno1,2, M Dovizio1,2, E Piazuelo3, L Di Francesco1,2,
A Contursi1,2, M Zucchelli2, S Schiavone1,2, S Tacconelli1,2, C Patrono4 and A Lanas3
The mechanism of action of low-dose aspirin in the prevention of colorectal cancer (CRC) remains largely hypothetical. We
aimed to compare the effects of low-dose aspirin (100 mg/day for 7 days) given to 40 individuals undergoing CRC screening
on the extent of cyclooxygenase (COX)-1 acetylation at serine-529 (AceCOX-1), in blood platelets vs. colorectal mucosa, at 7
(group 1) and 24 h (group 2) after dosing. A significantly (P < 0.01) lower %AceCOX-1 was detected in colonic and rectal
mucosa (average 64%) vs. platelets (average 75%) in both groups. This effect was associated with an average 46% (P < 0.01)
and 35% (P < 0.05) reduction in prostaglandin (PG) E2 levels and phosphorylated S6 (p-S6) levels, respectively. Rectal
mucosal levels of p-S6/S6 significantly (P < 0.01) correlated with PGE2. These findings demonstrate that low-dose aspirin
produces long-lasting acetylation of COX-1 and downregulation of p-S6 in human colorectal mucosa, an effect that may
interfere with early colorectal carcinogenesis.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 A large body of evidence supports a chemopreventive effect
of low-dose aspirin against CRC; however, its cellular target(s)
remains largely hypothetical.
WHAT QUESTION DID THIS STUDY ADDRESS?
 To what extent and for how long does low-dose aspirin acet-
ylate COX-isozymes in normal colorectal mucosa as compared
to blood platelets in subjects undergoing CRC screening.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 We demonstrate that low-dose aspirin persistently inhibits
COX-1 activity expressed in colorectal mucosa, thus restraining
PGE2 biosynthesis and S6 phosphorylation, an important com-
ponent of colorectal tumorigenesis.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Our findings of two distinct drug targets of low-dose aspirin
pharmacodynamics may help design dose-finding studies address-
ing the optimal dosing regimen for CRC prevention. Moreover, it
may offer an investigational paradigm for studies of other cancer
sites potentially targeted by aspirin chemoprevention.
A large body of evidence supports a chemopreventive effect of
low-dose aspirin against colorectal cancer (CRC).1,2 However,
the mechanism of action remains largely hypothetical.
Inhibition of ubiquitous cyclooxygenase (COX)-dependent
prostanoid production is necessary and sufficient to explain the
multifaceted clinical readouts of aspirin pharmacodynamics.3,4
Although other mechanisms have been proposed to explain its
chemopreventive effect, COX-isozymes remain the only drug tar-
get inhibitable at low micromolar aspirin concentrations in vitro
and following oral administration of low doses in vivo,5 and for
which a crystal structure has been obtained explaining target
function modification by the drug.6
An inhibitory effect on COX-2-dependent inflammation
represents a widely accepted mechanism to explain the chemopre-
ventive effect of aspirin and other nonsteroidal antiinflammatory
drugs (NSAIDs).7 However, whether COX-2 is expressed in
healthy colorectal mucosa remains controversial, and whether
low-dose aspirin can inhibit mucosal COX-2 activity in vivo has
not been previously investigated.
Constitutive expression of COX-1 in the gastrointestinal (GI)
mucosa is generally considered to subserve housekeeping func-
tions, such as mucosal cytoprotection, through prostaglandin
(PG)E2 production,
4 but its role in colorectal carcinogenesis has
only been explored in a murine model of intestinal polyposis.8 It
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has been proposed that in early stages of intestinal tumorigenesis,
enhanced colorectal PGE2 biosynthesis might occur via constitu-
tively expressed COX-1 in association with the suppression of
the PG-catabolizing enzyme, 15-prostaglandin-dehydrogenase
(15-PGDH), before the induction of COX-2.9 However, the
occurrence of this mechanism in vivo remains to be
demonstrated.
Micromolar concentrations of aspirin cause irreversible inhibi-
tion of COX-1 activity by acetylating a serine 529 (Ser529) resi-
due near the catalytic site of the enzyme.6,10,11 Although previous
studies have reported reduced GI levels of PGE2 in response to
low-dose aspirin,12–14 a potential contribution of platelet PGE2
inhibition cannot be excluded because of platelet activation
during and after tissue biopsy. No previous study has directly
examined the extent and duration of COX-1 acetylation in colo-
rectal mucosa by low-dose aspirin and its impact on local PGE2
production.
Thus, we designed a study to address the following related
questions: 1) which COX-isozyme is expressed by apparently
healthy colorectal mucosa, and provides the primary source of
PGE2 production in subjects undergoing CRC screening; 2) to
what extent is colorectal mucosa COX-1 acetylated by low-dose
aspirin as compared to platelet COX-1; 3) is acetylation of
COX-1 in the colorectal mucosa a reversible process because of
de novo synthesis of the enzyme by nucleated cells, and is it
accompanied by measurable reduction in PGE2 production; and
4) is there a detectable reduction in the expression of proteins
involved in the pathophysiology of CRC. Among the different
signaling pathways of intestinal tumorigenesis, we studied the
impact of low-dose aspirin on the extent of phosphorylation of
ribosomal protein S6. It may occur at Ser235/236 by p70S6K,
which is directly activated by the mammalian target of rapamycin
(mTOR)15 and by other kinases, including PKA.16,17 The phos-
phorylation of S6 increases the affinity of the 40S ribosomal sub-
unit to a subclass of mRNAs, and thus promotes their efficient
translation, and seems to play a potential role in regulating cell
growth capacity.18
RESULTS
We performed a short-term, randomized study of 40 subjects under-
going CRC screening who received enteric-coated (EC)-aspirin
100 mg/day (Adiro; supplied by Bayer-Schering Pharma, Berlin,
Germany) for 7 days before the colonoscopy. The inclusion and
exclusion criteria are detailed in the Supplementary Methods.
Consenting subjects were randomly allocated to group 1 (n5 20)
or group 2 (n 5 20), and peripheral blood and tissue samples
(biopsies of the rectal-sigmoidal segment and left and right colon)
were collected at 7 and 24 h after the last dose of aspirin, respec-
tively (Figure 1). The two groups were characterized by similar
demographic and clinical characteristics, including concomitant
pharmacologic treatments (Supplementary Tables S1, S2).
Assessment of plasma levels of acetylsalicylic acid (ASA) and
salicylic acid (SA) and biomarkers of platelet inhibition
At 7 h after the last dose of aspirin (group 1), plasma levels of
ASA and SA averaged 39.4 6 19.3 and 1,500 6 300 ng/mL,
respectively. In contrast, in group 2 (24 h after dosing), both
ASA and SA were undetectable (data not shown).
We assessed the effects of low-dose aspirin on the extent and
duration of platelet COX-1 acetylation at Ser529 (AceCOX-1).
As shown in Table 1 and Figure 2, at 7 h (group 1) the extent
of platelet COX-1 acetylation averaged 74.8 6 8.1% and was not
significantly different from the mean value found at 24 h after
dosing (group 2: 75.2 6 8.8%). This effect was associated with
virtually complete suppression of platelet COX-1 activity
(>97%), as reflected by TXB2 production during whole blood
clotting (serum TXB2),
19,20 in both groups (Table 1). Aspirin
caused comparable inhibition of platelet function, as assessed by
the PFA-100 diagnostic system with collagen/epinephrine test
cartridge,20 7 and 24 h after dosing (Table 1). Aspirin also caused
similar reductions in the urinary excretion of TX-M, an index of
TXA2 biosynthesis in vivo
21,22 in both groups (Table 1).
Expression of proteins involved in PGE2 biosynthesis and
catabolism and PGE2 levels in normal rectal biopsies
We studied the expression levels of COX-1, COX-2, mPGES-1
(microsomal PGE synthase-1), and 15-PGDH in the rectal
mucosa of subjects of both groups, at baseline and after aspirin
treatment (Figure 3a–c). Mucosal expression of COX-1 was
assessed by LC-MS/MS20,23; aspirin did not affect total
protein concentration (AceCOX-11COX-1) in either group
(Figure 3a).
No detectable expression of COX-2 was found by western blot
analysis; the results of representative biopsies collected in three
different individuals are shown in Figure 3b. mPGES-1
and 15-PGDH levels, assessed by western blot, are reported in
Figure 3b,c. In both groups, aspirin treatment did not significant-
ly affect the levels of these proteins. Small changes in 15-PGDH
levels were detected in some individuals after aspirin treatment,
both in group 1 (Figure 3b,c) and group 2 (Figure 3c).
PGE2 is a major prostanoid produced in the colorectal muco-
sa.24 Before aspirin administration, similar levels of PGE2 were
measured in rectal mucosal biopsies collected at baseline in groups
1 and 2 (5.8 6 2.9 and 6.2 6 2.9 pg/lg protein, respectively)
(Figure 3d). Treatment with low-dose aspirin caused a significant
(P < 0.01) reduction in PGE2 levels by 43% in group 1 and 50%
in group 2 (Figure 3d), suggesting a persistent inhibitory effect of
aspirin on mucosal COX-1 activity up to 24 h after dosing.
Assessment of COX-1 acetylation in biopsies of normal
colorectal mucosa
We used a previously described liquid chromatography/tandem
mass spectrometry (LC-MS/MS) technique to measure the
extent of COX-1 acetylation at Ser529,20,23 in proteolyzed biop-
sies of the intestinal mucosa. As shown in Figure 2, at 7 and
24 h after aspirin (groups 1 and 2, respectively), %AceCOX-1 in
apparently normal rectal mucosal biopsies averaged 61 6 9% and
66 6 8%, respectively.
AceCOX-1 was also detected in biopsies of the left and right
colon in both groups (Figure 2); %AceCOX-1 values were
not significantly different from the values found in the rectal
mucosa. The values of %AceCOX-1 in colorectal mucosa were
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significantly lower (P < 0.01) than those measured in platelets,
both at 7 and 24 h after dosing.
Effects of low-dose aspirin on rectal mucosal expression of
proteins involved in the pathophysiology of colorectal cancer
In addition to the proteins of the enzymatic machinery responsi-
ble for PGE2 biosynthesis and catabolism, we assessed the impact
of aspirin treatment on rectal mucosal levels of EGFR (epidermal
growth factor receptor)25 and S6. EGFR levels were not affected
by the drug (Supplementary Figure S1). Similarly, average values
of S6 levels detected in both groups were not significantly affect-
ed by low-dose aspirin (Figure 4a); however, some changes were
detected in some individuals of group 1 (Figure 4b) and group 2
(not shown). The drug caused a significant reduction (P < 0.05)
(a)
(b)
Figure 1 Flow diagram of the study phases (a) and flow chart of the study protocol (b). [Color figure can be viewed at wileyonlinelibrary.com]
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in the phosphorylation of S6 (p-S6), in both groups (Figure 4b,c).
Bivariate linear regression analysis showed that the values of rec-
tal mucosal p-S6/S6 significantly (P < 0.01) correlated with the
levels of PGE2, assessed in the same samples (Figure 4d).
Effect of low-dose aspirin on systemic biosynthesis
of PGE2 and PGI2
Our population included 19 individuals (47.5%) with polyps/
colorectal adenomas/adenocarcinomas (Supplementary Table S1).
Thus, we studied whether the systemic biosynthesis of PGE2 is
altered in this setting by assessing the urinary levels of PGE-M, a
major enzymatic metabolite of PGE2.
26 Median (range) baseline
values of urinary PGE-M excretion were 10.6 (4.4–48.7) ng/mg
creatinine (Figure 5a). Multivariate regression analysis showed
that none of the demographic and clinical variables and drug treat-
ments made a significant contribution to baseline PGE-M levels.
In the 19 individuals with polyps/adenomas/adenocarcinomas,
median values of PGE-M were substantially unchanged: 10.0
(4.6–48.7) ng/mg creatinine (not shown). After dosing with
low-dose aspirin, median urinary PGE-M excretion measured in
both groups was 9.3 (3.6–30.2) ng/mg creatinine (Figure 5a).
The use of a nonparametric paired analysis showed that aspirin
caused a significant (P < 0.05) reduction in PGE-M excretion
vs. baseline (Figure 5a).
Low-dose aspirin did not significantly affect the urinary levels
of PGI-M, a major enzymatic metabolite of prostacyclin mainly
derived from vascular COX-227 (Figure 5b).
Effects of aspirin on intestinal epithelial COX-1 and
COX-2 and platelet COX-1 activities in vitro
In quiescent human intestinal epithelial cells (expressing COX-1,
but not COX-2: Figure 6a), aspirin inhibited PGE2 production
in a concentration-dependent fashion, with an IC50 value of
8.3 lmol/L (95% confidence interval, CI, 4.6–15.2) (Figure 6b).
The inhibitory effect of aspirin on COX-2-dependent PGE2 was
assessed in cells expressing COX-2 following their incubation
with 2 ng/mL of interleukin-1 beta (IL-1b) for 12 h (Figure 6a).
Under these experimental conditions, aspirin inhibited PGE2
production, in a concentration-dependent fashion, with an IC50
value of 12.0 lmol/L (95% CI, 6.9–22.8) (Figure 6b). Finally,
we characterized the potency of aspirin in inhibiting TXB2 pro-
duction in human platelets. In washed platelets (expressing only
COX-1, Supplementary Figure S2), aspirin reduced platelet
TXB2 production, in a concentration-dependent fashion, with
an IC50 value of 8.2 lmol/L (95% CI, 4.8–14.1) (Figure 6b).
Stability and rate of de novo synthesis of COX-1 and COX-2 in
human intestinal epithelial cells in vitro
In the presence of the protein synthesis inhibitor cycloheximide
(CHX, 50 lmol/L final concentration), COX-1 protein levels
remained stable up to 24 h (Figure 6c) while COX-2 levels,
induced in response to IL-1b, decreased in a time-dependent
fashion with a t1=2 of 3 h (Figure 6c).
We studied the rate of recovery of PGE2 biosynthesis in epithe-
lial cells (expressing only COX-1) and in a human colonic adeno-
carcinoma cell line (HCA7 cells, which constitutively express only
COX-2, Supplementary Figure S2), after treatment with aspirin
(50 lmol/L) for 1 h followed by drug washout. At 24 h after aspi-
rin exposure, 50% of COX-1 activity was recovered, while
COX-2 activity was almost completely restored (Figure 6d).
Effect of repeated exposure to aspirin on epithelial
COX-1-dependent PGE2 production in vitro
Epithelial cells were exposed for 1 h to aspirin (2.5 lmol/L) and
the drug was washed away from the cells; this was repeated once
daily up to 72 h. The activity of COX-1 was induced by the incu-
bation with arachidonic acid (AA) (20 lmol/L) for 60 min. As
shown in Figure 6e, a cumulative inhibition of PGE2 production
was caused by repeated exposure of epithelial cells to a low concen-
tration of aspirin.
DISCUSSION
Several lines of evidence support a chemopreventive effect of aspi-
rin against CRC.1–3 However, prevention of sporadic colorectal
polyp recurrence represents the only clinical setting in which the
chemopreventive effects of low- to medium-dose aspirin and
Table 1 Antiplatelet effects of low-dose aspirin evaluated using
direct and indirect biomarkers of drug action
Group 1 Group 2 P
AceCOX-1(%) 74.8 6 8.1 75.2 6 8.8 0.899
Serum TXB2 (% inhibition) 97.4 6 2.8 97.6 6 1.4 0.761
PFA-100 (CEPI-CT, % of baseline) 205.4 6 52.9 200.0 6 58.5 0.772
TX-M (% inhibition) 68.0 6 13.8 69.0 6 16.5 0.837
Values are mean 6 SD, n 5 20/group; P values are for the mean comparisons of














































Figure 2 Low-dose aspirin acetylates COX-1 in platelets and apparently
normal colorectal mucosa. Using an LC-MS/MS technique, acetylated
COX-1 vs. total COX-1 (%AceCOX-1) in homogenized platelets and biopsies
collected from the rectum and the left and right colon of group 1 and
group 2 (at 7 and 24 h following the last aspirin dose, respectively) was
assessed. Data are reported as mean 6 SEM, n 5 20/group. **P < 0.01
vs. platelets.
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medium- to high-dose coxibs (selective COX-2 inhibitors) have
been examined prospectively in placebo-controlled randomized
trials.3,28 The results of these trials demonstrate that: 1) the che-
mopreventive effect of aspirin is apparent at daily doses as low as
81 mg; 2) it does not display dose-dependence in a head-to-head
dose comparison; and 3) a protective effect against colorectal
tumorigenesis is also found with coxibs.3 The current knowledge
of the human pharmacodynamics of low-dose aspirin (i.e., a selec-
tive inhibitor of platelet COX-1 activity) and coxibs (i.e., selec-
tive inhibitors of COX-2 activity) supports the hypothesis that
both COX-isozymes contribute to intestinal tumorigenesis.3,29,30
It has been proposed that COX-1-dependent platelet activation,
occurring at sites of persistent mucosal injury, may participate in





Figure 3 Effects of low-dose aspirin on the levels of COX-1, COX-2, mPGES-1, 15-PGDH, and PGE2, in apparently normal rectal mucosal biopsies. In rectal
mucosal samples collected at 7 and 24 h after the last dose of aspirin (groups 1 and 2, respectively), we evaluated (a) COX-1 concentrations (AceCOX-
11COX-1) (fmol/lg protein) by LC-MS/MS, (b) COX-2, mPGES-1, 15-PGDH, and b-actin protein levels (by western blot, the analysis of three representative
biopsies collected in different individuals of group 1 is shown), (c) densitometric analysis of western blot bands of mPGES-1 and 15-PGDH normalized to
b-actin, (d) PGE2 levels (pg/lg protein; by immunoassay). Data are reported as mean 6 SEM, n 5 20/group (a,c,d). **P < 0.01 vs. baseline (d).
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release of a plethora of soluble mediators (i.e., lipids, cytokines,
and growth factors) and membrane vesicles (rich in genetic mate-
rial, including microRNAs).29 This hypothesis would explain the
apparently similar chemopreventive effect of low-dose aspirin act-
ing upstream to suppress platelet activation at sites of intestinal
mucosal injury and coxibs acting downstream to inhibit COX-2
activity in stromal and intestinal epithelial cells.
However, this interpretation remains highly hypothetical in
the absence of a quantitative assessment of platelet vs. extraplate-
let COX-1 acetylation by low-dose aspirin.
Using a novel proteomic assay that allows assessing the extent
of acetylation of COX-1 at Ser529 in cells/biopsies,20,23 we were
able to demonstrate that low-dose aspirin can cause a persistent
acetylation of constitutively expressed COX-1 in rectal and left
and right colonic mucosa.
Low-dose aspirin was more effective in acetylating COX-1 in
blood platelets than in colorectal mucosa, despite inhibiting
COX-1 activity with comparable potency in intestinal epithelial
cells and platelets in vitro (refs. 31,32, and the present study). The
exposure of platelets to a higher concentration of intact ASA in
the presystemic circulation33 is a plausible determinant of the
higher extent of acetylation of COX-1 in platelets than colorectal
mucosa demonstrated in the present study.
Acetylation of rectal mucosal COX-1 by low-dose aspirin was
associated with an 50% reduction in PGE2 levels, which per-
sisted up to 24 h after dosing. We found that both the stability
of COX-1 (up to 24 h) and the slow-rate of recovery of COX-1
activity might explain the long-term persistence of enzyme acety-
lation and product inhibition. Thus, 24 h after the exposure to
an aspirin concentration which causes a substantial inhibition of
(a) (b)
(c) (d)
Figure 4 Effects of low-dose aspirin on the rectal mucosal levels of S6 and its phosphorylation. (a,c) Quantification of S6 and its phosphorylated form
p-S6 in rectal mucosa of all individuals (groups 1 and 2, samples collected at 7 and 24 h after the last aspirin dose, respectively) by western blot
(normalized to b-actin values); baseline is predrug and Aspirin is postdrug. (b) A representative western blot analysis of biopsies collected from three
individuals of group 1 is shown. (d) Linear regression analysis between rectal mucosal PGE2 levels (pg/lg protein) and the p-S6/S6 (OD ratio) (log10
transformation of values) measured in the same samples. Data are reported as mean 6 SEM, n 5 20/group (a,b). *P < 0.05 vs. baseline (b).
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COX-1 activity, the enzyme is still profoundly inhibited, and
repeated daily exposure to aspirin in vitro is associated with a
cumulative inhibition of PGE2 production. This is analogous to
the cumulative inhibition of platelet TXB2 production upon
repeated daily dosing with very low doses of aspirin.34
In the present study, rectal mucosal PGE2 levels correlated
with the extent of phosphorylation of S6 and low-dose aspirin
caused a significant reduction in the phosphorylation of the
protein.
Din et al.35 previously reported that aspirin reduces S6 phos-
phorylation in CRC cells in vitro at millimolar concentrations.
Moreover, rectal mucosal samples from patients given aspirin
600 mg daily for 1 week had reduced phosphorylation of S6.35
The authors concluded that aspirin is an inhibitor of mTOR and
an activator of AMPK, targeting regulators of intracellular energy
homeostasis and metabolism. Here we report that the administra-
tion of low-dose aspirin caused a significant reduction in rectal
mucosal S6 phosphorylation at 7 h after dosing, at a time of cir-
culating micromolar concentrations of ASA. The persistence of
this effect up to 24 h after dosing (when no levels of ASA were
detectable) is consistent with aspirin acting by an irreversible
mechanism. Together with the significant relationship of rectal
mucosal p-S6/S6 values with PGE2 levels, these results suggest
that COX-1-dependent PGE2 inhibition by low-dose aspirin
may explain downstream S6 phosphorylation.
We provide evidence that a low concentration of aspirin is
inadequate to cause a persistent inhibitory effect on epithelial
COX-2-dependent PGE2 biosynthesis in vitro. In fact, the effect
on PGE2 production was completely reversed at 24 h. These
results might suggest the inability of low-dose aspirin to cause a
cumulative effect upon repeated daily dosing. However, this issue
should be investigated in an appropriate study of patients with
COX-2-expressing CRC, using a direct marker of aspirin action.
We assessed the impact of low-dose aspirin on indices of
COX-2 activity in vivo, such as urinary PGE-M26 and PGI-M
excretion.27 We found a significant (P < 0.05) small reduction
of median values of urinary PGE-M by low-dose aspirin while
urinary PGI-M levels did not differ to any statistically significant
extent. These assessments were secondary endpoints and the sta-
tistical power of the clinical study was inadequate to detect mod-
erate treatment effects. Recently, Boutaud et al.32 reported that
low-dose aspirin reduced urinary PGE-M and PGI-M levels by
45% and 37%, respectively, in a larger population of healthy
subjects.
The limitations of our study include: 1) given the nature, dura-
tion, and sample size, we could not assess any clinical end-point;
2) in the absence of detectable COX-2 expression in colorectal
mucosa biopsies, we could not directly assess the extent and dura-
tion of COX-2 acetylation throughout the 24-h dosing interval.
The strengths are represented by: i) use of a recently developed
proteomic approach to quantitate the extent of COX-1 acetyla-
tion20,23 in blood and tissue cellular targets of aspirin pharmaco-
dynamics; ii) two randomized groups of subjects, in whom
pharmacokinetic/pharmacodynamic assessment was performed
shortly after peak plasma levels of intact ASA in the systemic cir-
culation and at 24 h after dosing; and iii) in vitro experiments to
characterize the stability of COX-1 vs. COX-2 protein, and
cumulative nature of COX-1 acetylation in colorectal mucosa.
In conclusion, aspirin 100 mg once daily can persistently acety-
late intestinal COX-1, thus affecting colorectal mucosa PGE2
biosynthesis and the phosphorylation of S6. Our results suggest
that the concurrent inhibitory effect of low-dose aspirin on
COX-1 in platelets and colorectal mucosa might explain its pre-
ventive efficacy against recurrence of a colorectal adenoma3,28
and its longer-term chemopreventive benefit against CRC in the
setting of primary cardiovascular prevention.37
METHODS
Clinical study: design, treatments, and biomarker assessment
The main objectives of this study were: 1) to verify whether low-dose
aspirin causes persistent acetylation of COX-1 in platelets, but not in
nucleated cells of the recto-colonic tissue 24 h after dosing when no cir-
culating levels of ASA are detectable20; 2) to assess whether at the time
when aspirin reaches its maximal concentration in the systemic circula-
tion (7 h),20 COX-1 of platelets and colorectal mucosa is acetylated to
a different extent; 3) to evaluate whether differential acetylation of
COX-1 translates into complete (in platelets) vs. incomplete (in colorec-
tal mucosa) suppression of prostanoid production. The percentage of
















































Figure 5 Effect of low-dose aspirin on the systemic biosynthesis of PGE2
and PGI2. Urinary PGE-M levels (ng/mg creatinine) (a) and PGI-M levels
(pg/mg creatinine) (b) at baseline and after low-dose aspirin treatment.
Data (n 5 40) are reported as a box-and-whisker plot with individual data
points; the line represents the median value. *P < 0.05 vs. baseline (a).
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colorectal mucosa biopsies was assessed by the absolute quantification
(AQUA) method using an LC-MS/MS technique, as previously
reported20,23 and briefly described in the Supplementary Methods. The
impact of low-dose aspirin treatment was evaluated on: 1) platelet
COX-1 activity, by assessing serum TXB2 levels
19,20,34; 2) platelet
function by using the whole-blood PFA-100 as previously described20;
3) PGE2 biosynthesis assessed by a validated immunoassay
38 and the
expression of proteins involved in CRC development (COX-1, COX-2,
mPGES-1, 15-PGDH, EGFR, and S6, both native protein and phos-





Figure 6 In vitro characterization of aspirin inhibitory effects on COX-isozyme activity and protein stability in epithelial cells and platelets. (a) Analysis of
COX-1, COX-2, and b-actin protein levels in intestinal epithelial cells (untreated or stimulated with IL-1b (2 ng/mL) for 12 h) by western blot. (b)
Concentration-dependent inhibitory effect of aspirin (ASA) on COX activity, assessed by measuring PGE2 levels in untreated intestinal epithelial cells
(epithelial COX-1), in IL-1b-stimulated intestinal epithelial cells (epithelial COX-2), and TXB2 levels in washed platelets (platelet COX-1). (c) The stability of
COX-1 and COX-2 proteins, in untreated and IL-1b-stimulated intestinal epithelial cells, respectively, was assessed in the presence of cycloheximide
(CHX; 50 lmol/L final concentration) for the indicated times and then cell lysates were prepared and analyzed by western blotting for COX-1, COX-2, and
b-actin. (d) Time-dependent recovery of COX-1 and COX-2 activity by aspirin-treated intestinal epithelial cells and HCA7 cells, respectively; cells were
treated for 1 h with aspirin 50 lmol/L, then the cells were washed to remove aspirin and, at the indicated times, percent inhibition of COX-1 and COX-2
activity vs. baseline was assessed by measuring PGE2 levels induced by the addition of AA (20 lmol/L) or (0.5 lmol/L), respectively, for 1 h. (e)
Cumulative inhibition of epithelial cell COX-1 activity by daily exposure to very low concentrations of aspirin (2.5 lmol/L) or vehicle (DMSO) for 1 h; then
the drug was washed away from the cells and this treatment was repeated once daily up to 72 h and the activity of COX-1 was assessed as described
above. Data are reported as mean 6 SEM, n 5 3-7 (b–e); **P < 0.01 vs. 24 h for COX-2 (d); *P < 0.05 vs. 1 h (e).
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western blot, as detailed in the Supplementary Methods. Finally, we
assessed the impact of low-dose aspirin on biomarkers of the in vivo
activity of COX-2, by assessing the urinary excretion of major enzymatic
metabolites of PGE2 and PGI2, i.e., 11-a-hydroxy-9,15-dioxo-2,3,4,5-
tetranor-prostane-1,20-dioic acid (PGE-M) and 2,3-dinor-6-keto-PGF1a
(PGI-M), respectively,39,40 and COX-1 by assessing the urinary excretion
of a major enzymatic metabolite of TXA2, i.e., 11-dehydro-TXB2 (TX-
M),21,22 using previously described methods.22,39,40 Due to the complexi-
ty of the clinical protocol, urinary samples were collected in all individu-
als, during the last 10 h (overnight) after the 6th dose of low-dose
aspirin (administered in the morning).
The study was conducted in accordance with the Declaration of Hel-
sinki, and the protocol was approved by the Clinical Investigation Ethics
Committee of the Aragon Health Research Institute (Zaragoza, Spain)
(EUDRACT number: 2013-004269-15; ClinicalTrials.gov Identifier:
NCT02125409). All subjects provided written informed consent.
The study was performed at Hospital Clinico Universitario Lozano
Blesa (Zaragoza, Spain) and all biomarker assessments were carried out
at CeSI-MeT (Chieti, Italy).
In vitro studies in human intestinal epithelial cells, platelets
and human colon cancer cell line HCA-7
The experimental methods are reported online in the Supplementary
Information.
Statistical analysis
The data are expressed as mean 6 SD, unless otherwise stated, and statis-
tical comparisons were made by parametric tests (Student’s t-test
or repeated-measures analysis of variance followed by the Student–
Newman–Keuls test). Data that did not pass the normality test (by the
method of Kolmogorov and Smirnov) are reported as median and range
(minimum and maximum) and analyzed using nonparametric tests. A
probability value of P < 0.05 was considered statistically significant. The
primary endpoint of the study was the assessment of COX-1 acetylation
in platelets vs. nucleated cells of the colonic tissue, at 24 h after dosing.
The primary hypothesis was that the administration of EC-aspirin would
cause a maximal acetylation of platelet COX-1 (70%) while causing a
marginal acetylation (<10%) of COX-1 in colonic tissue, at 24 h after
dosing (group 2). The secondary hypothesis was that after 7 h of aspirin
administration (group 1), the drug would cause maximal acetylation of
platelet COX-1 associated with 20–30% COX-1 acetylation in intestinal
tissue. Based on a previous study performed in healthy subjects, we calcu-
lated an intersubject coefficient of variation (CV) of platelet AceCOX-1
of 10%, at 24 h after aspirin administration for 7 days.20 Assuming this
intersubject CV, a sample size of 20 patients would allow detection of a
difference of 14% or higher in percent acetylation between platelets vs.
colonic tissues, with a power of 99%, by two-tailed tests, with probability
values less than the type I error rate of 0.05. Thus, we would be able to
obtain significant differences of AceCOX-1 in platelets vs. colonic tissue
both at 24 (group 2) and at 7 h (group 1) after dosing.
Additional Supporting Information may be found in the online version of
this article.
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